DadFinStart your free week
DadFin › Stocks › Healthcare › AQST

Aquestive Therapeutics, Inc. (AQST) stock score

Healthcare · Drug Manufacturers - Specialty & Generic · United States

$4.78 ▲ +0.42% today

12.6
Dad Score, out of 100
poor

Aquestive Therapeutics, Inc. (AQST) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, listed in the United States. On DadFin's weekly run it scores 12.6 out of 100 on the Dad Score, a poor reading that places the business ahead of 13% of the 5,774 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #848 of 974. Its weakest axes are quality, growth and price action.

Scores from the run of Oct 4, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Average
Quality
Below average
Growth
Weak
Price action
Below average
Risk
Average
Conviction
Below average
Liquidity
Below average
Macro
Average

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)0.0×
P/E (forward)-8.0×
Dividend yield0.00%
Return on capital-59.1%
Operating margin-59.5%
Revenue growth (YoY)-22.6%
FCF yield-10.9%
Net debt / EBITDA3.00×
Piotroski F-Score2 / 9
52-week change-23.8%
Market cap$571M
Next earningsNov 4, 2026

What subscribers see on AQST

Start your free weekSubscriber? Open the full research →

Drug Manufacturers - Specialty & Generic peers

StockCompanyDad ScoreBandMarket cap
TAKTakeda Pharmaceutical Company Limi32.9weak$57.1B
TEVATeva Pharmaceutical Industries Lim93.6strong$46.1B
HLNHaleon plc64.5middling$38.7B
ZTSZoetis Inc.61.2middling$28.8B
UTHRUnited Therapeutics Corporation99.8strong$23.2B
VTRSViatris Inc.54.4middling$20.2B
NBIXNeurocrine Biosciences, Inc.98.4strong$14.6B
ELANElanco Animal Health Incorporated84.0good$11.1B

Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 4, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.